£2.2M Collaboration to Fuel Drug Developments for HIV
A collaboration between the University of Liverpool and the Johns Hopkins University School of Medicine (JHUSM) has been awarded a further £2.2m ($3M) to develop sophisticated new medicines for HIV.
The researchers have received the award from the National Institutes of Health (NIH) to generate new technologies for long-acting administration of antiretroviral drugs. Conventional therapies rely on oral dosing and tablets which weigh heavily on many patients, with missed doses contributing to the development of viral resistance.
The research in Liverpool, conducted by the cross-Faculty Nanomedicine Partnership led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, will further examine the use of nanotechnology to improve the delivery of drugs to HIV patients through novel implantable technologies that can deliver drugs for weeks or months.
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. This evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
The Liverpool Nanomedicine Partnership have previously undertaken the world’s first human trials of orally dosed nanomedicines for HIV and this is the latest collaboration in a series of productive research efforts with Johns Hopkins University School of Medicine to target long-acting implantable therapy options.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Professor Steve Rannard, said: “We are looking at strategies that remove the need for daily tablets and generate long-acting dosing technologies that may be able to provide therapeutic drug concentrations for months after a single administration.
“This latest grant demonstrates ongoing support from the NIH for the trans-Atlantic collaboration between the University’s Nanomedicine Partnership and the Johns Hopkins University School of Medicine.
Professor Andrew Owen, said “This project continues to harness the expertise from both Liverpool and Baltimore, which embraces organic chemistry, materials chemistry, and pharmacology, with significant clinical input to drive strategy.
“There is a seamless link with our ongoing collaborations with Johns Hopkins, which is built upon a shared ambition to bring affordable state-of-the-art medicines to the patients that we serve.”
Dr Caren Meyers, Associate Professor of Pharmacology and Molecular Sciences at JHUSM, said: “The synergistic partnership between the University of Liverpool and the Johns Hopkins University School of Medicine has enabled the smooth translation of basic medicinal chemistry and materials science concepts to proof-of-concept preclinical models.
“This award will push forward our collaborative efforts to meet a need for complete long-acting therapeutic options for HIV.”
This article has been republished from materials provided by the University of Liverpool. Note: material may have been edited for length and content. For further information, please contact the cited source.
Scientists Develop a Synthetic Solution to Combat Dwindling Supply of Cancer and HIV DrugNews
Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
New Drug Class: Potential Therapeutics for Alzheimer’s Disease?News
One step closer to an Alzheimer's treatment? Novel class of drugs more precisely blocks production of toxic forms of beta-amyloid.READ MORE